Figure 5.

AAV orexin rescued the timing of wakefulness. A, WT mice injected with AAV-mCherry produce very long wake bouts in the fi rst 2 h of the dark period. B, A similar pattern is seen in WT mice injected with AAV-orexin though these very long wake bouts persist for about 4 h. C, Unrescued Atx mice injected with AAV-mCherry have short wake bouts at all times, even at dark onset. D, In contrast, Atx mice injected with AAV-orexin produce long wake bouts in the fi rst 2 h of the dark period, much like normal WT mice. Maximum wake bouts were calculated using a 1 h-wide moving window as described in the Methods section. Data are shown as group mean (solid lines) ± standard error of the mean (dashed lines). The triangles represent signifi cant differences from WT mice injected with AAV-mCherry, whereas the vertical bars denote signifi cant differences between AAV-orexin and AAV-mCherry treated Atx mice after Bonferroni post hoc tests (P < 0.05). AAV, adeno-associated viral vector; Atx, transgenic (ataxin); WT, wild type.